ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has been granted a $2.1 million Technology/Therapeutic Development Award through the US Department of Defense Peer Reviewed Medical Research Program (PRMRP).

This entry was posted in Recent Development News: Q4 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »